At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BIAF bioAffinity Technologies, Inc.
Pre-Mkt 04-07 05:40:15 EDT
4.18
+0.26
+6.63%
盘前4.10
-0.08-1.91%
05:37 EDT
High4.19Low3.77Vol1.41M
Open3.82D1 Closing3.92Amplitude10.71%
Mkt Cap18.80MTradable Cap14.22MTotal Shares4.50M
T/O5.64MT/O Rate41.52%Tradable Shares3.40M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BioAffinity’s CyPath Lung Test unit sales surged 146% y/y in Q1
TIPRANKS  ·  04-01
BioAffinity’s CyPath Lung Test unit sales surged 146% y/y in Q1
bioAffinity CyPath Lung unit sales jump 146% in Q1 2026
Reuters  ·  04-01
bioAffinity CyPath Lung unit sales jump 146% in Q1 2026
What's Going On With bioAffinity Technologies Stock Wednesday?
Benzinga  ·  03-25
What's Going On With bioAffinity Technologies Stock Wednesday?
bioAffinity Technologies to host live virtual physician roundtable; CyPath Lung adoption grows in pulmonary practice discussion
Reuters  ·  03-25
bioAffinity Technologies to host live virtual physician roundtable; CyPath Lung adoption grows in pulmonary practice discussion
Why Is bioAffinity Technologies Stock Surging Tuesday?
Benzinga_recent_news  ·  03-17
Why Is bioAffinity Technologies Stock Surging Tuesday?
bioAffinity Technologies releases CyPath Lung case study highlighting 92% sensitivity in nodules under 20 mm
Reuters  ·  03-17
bioAffinity Technologies releases CyPath Lung case study highlighting 92% sensitivity in nodules under 20 mm
BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen Bio
Reuters  ·  03-14
BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen Bio
bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth
Benzinga  ·  03-13
bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth
bioAffinity Technologies FY2025 net loss widens 66% to USD 14.91 million on revenue down 34% to USD 6.16 million
Reuters  ·  03-13
bioAffinity Technologies FY2025 net loss widens 66% to USD 14.91 million on revenue down 34% to USD 6.16 million
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic Cypath® Lung
THOMSON REUTERS  ·  03-13
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic Cypath® Lung
BioAffinity Technologies initiates clinical study for CyPath Lung
TIPRANKS  ·  03-10
BioAffinity Technologies initiates clinical study for CyPath Lung
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive Cypath® Lung Cancer Diagnostic
THOMSON REUTERS  ·  03-10
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive Cypath® Lung Cancer Diagnostic
bioAffinity Technologies directors Robert Anderson and Roby Joyce to step down at April 30 annual meeting
Reuters  ·  03-07
bioAffinity Technologies directors Robert Anderson and Roby Joyce to step down at April 30 annual meeting
bioAffinity Technologies reports positive findings for asthma therapy-matching sputum diagnostic platform
Reuters  ·  03-03
bioAffinity Technologies reports positive findings for asthma therapy-matching sputum diagnostic platform
BRIEF-Bioaffinity Announces Validation Study For Lung Cancer Test
Reuters  ·  02-25
BRIEF-Bioaffinity Announces Validation Study For Lung Cancer Test
bioAffinity Technologies Partners With Brooke Army Medical Center on CyPath Lung Validation Study
Reuters  ·  02-25
bioAffinity Technologies Partners With Brooke Army Medical Center on CyPath Lung Validation Study
bioAffinity Technologies Announces Validation Study With Brooke Army Medical Center to Expand SAMPLE Collection Options for the Cypath® Lung Noninvasive Early Detection Lung Cancer Test
THOMSON REUTERS  ·  02-25
bioAffinity Technologies Announces Validation Study With Brooke Army Medical Center to Expand SAMPLE Collection Options for the Cypath® Lung Noninvasive Early Detection Lung Cancer Test
bioAffinity Technologies Highlights CyPath Lung Case Study Supporting Noninvasive Lung Cancer Surveillance
Reuters  ·  02-20
bioAffinity Technologies Highlights CyPath Lung Case Study Supporting Noninvasive Lung Cancer Surveillance
bioAffinity Technologies Showcases CyPath Lung Test Clinical Utility in Real-World Case Study
Reuters  ·  02-17
bioAffinity Technologies Showcases CyPath Lung Test Clinical Utility in Real-World Case Study
BioAffinity Technologies announces new appointments to Advisory Board
TIPRANKS  ·  02-09
BioAffinity Technologies announces new appointments to Advisory Board

Introduction

Company Name.
bioAffinity Technologies, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
Issue price:
--